PAR · ALTHE.PA
Theraclion S.A.
€0.74+€0.05 (+7.4%)
Theraclion S.A.’s quoted price sits in the upper half of its reported 52-week range, 20.43% below the high.
Loading market information…
PAR · ALIKO.PA · EUR
Stock price, earnings
Quote as of Oct 29, 2026, 01:24 PM UTC. Cached market data; not a live quote.
One-year closing-price history · EUR. Historical prices are not a forecast.
Ikonisys S.A.’s quoted price sits in the lower half of its reported 52-week range, 22.28% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Ikonisys S.A.’s next earnings report is currently expected on Mar 3, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Ikonisys S.A.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Based in Paris, France, Ikonisys S.A. is a company specializing in cell-based diagnostics. It develops, produces, and commercializes medical diagnostic solutions for various cancers across the United States and Europe. Their core offering includes the Ikoniscope Robotic Microscope, which automates slide manipulation, scanning, and real-time image acquisition and analysis, thereby minimizing human error during diagnostic testing. The company provides a suite of specialized oncoFISH microscopy applications for cancer detection and characterization, such as oncoFISH bladder for analyzing urine samples, oncoFISH her2 for determining HER2 status in breast tissue biopsies, oncoFISH ALK for identifying rearrangements of the ALK gene, and oncoFISH PTEN for detecting PTEN gene deletions in prostate tissue biopsies. Ikonisys also offers tools for characterizing individual circulating tumor cells (CTCs) and analyzing circulating tumor DNA (ctDNA) to provide comprehensive tumor genotype information. Additionally, their Ikonisoft explorer software suite features dedicated FISH scanning applications: Ikonisoft explorer CS for cell suspensions on slides, and Ikonisoft explorer tissue for examining hybridized tissue sections. Finally, the IkoniWAN Gateway provides a secure, validated remote access solution for their Ikoniscope digital microscopy platforms.
Latest available per-share figures in EUR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:30 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
€0.74+€0.05 (+7.4%)
Theraclion S.A.’s quoted price sits in the upper half of its reported 52-week range, 20.43% below the high.
€3.48+€0.02 (+0.58%)
THX Pharma’s quoted price sits in the upper half of its reported 52-week range, 31.76% below the high.
€0.94-€0.01 (-0.64%)
Diagnostic Medical Systems S.A.’s quoted price sits in the lower half of its reported 52-week range, 37.18% below the high.
€0.15+€0.00 (+0.54%)
Implanet S.A.’s quoted price sits in the lower half of its reported 52-week range, 47.62% below the high.
€0.07-€0.00 (-1.07%)
GenSight Biologics S.A.’s quoted price sits in the lower half of its reported 52-week range, 68.91% below the high.
€0.20-€0.00 (-0.98%)
Intrasense S.A.’s quoted price sits in the lower half of its reported 52-week range, 57.11% below the high.
€0.69+€0.02 (+2.53%)
Advicenne S.A.’s quoted price sits in the lower half of its reported 52-week range, 70.64% below the high.
€0.17+€0.01 (+6.46%)
Poxel S.A.’s quoted price sits in the lower half of its reported 52-week range, 64.29% below the high.
